Brain4

brain4care operates at the intersection of medical devices, neurotechnology, software, sensors, and wearables. Its differentiation is the attempt to monitor intracranial dynamics non-invasively through skull micro-expansions and a surrogate waveform, rather than relying exclusively on invasive intracranial pressure monitoring. That approach targets clinical situations where continuous or repeated assessment is useful but invasive placement is impractical, including ICU monitoring, outpatient evaluation, and shunt dysfunction diagnosis. The company therefore competes indirectly with conventional invasive monitoring systems from established medical-device providers such as Integra LifeSciences and Raumedic, as well as with non-invasive neurological-monitoring approaches used in hospitals. brain4care’s potential advantage is the combination of a wearable sensor, cloud-based analysis, subscription access, training, and clinical support. Its FDA 510(k) clearance and reported use across more than 210 accounts provide evidence of a commercialization pathway beyond laboratory research. However, the company remains relatively small, with an employee band of 11–50 and four disclosed financing rounds totaling $9.72 million.

brain4care’s trajectory shows a progression from early technical development to regulated clinical commercialization. The company was founded in 2014, raised a $500,000 pre-seed round in 2016, and followed with a $5 million seed round in 2018. A further $720,000 seed round in 2019 preceded its $3.5 million Series A on Sep 1, 2020, led by Miletus Fund, bringing disclosed financing to $9.72 million. Product development has expanded beyond a sensor alone: the company offers a non-invasive intracranial compliance monitoring system and a subscription service combining sensor leasing, software licensing, training, and support. Its reported footprint of more than 210 active accounts, 55,626 patients, and 95,647 sessions suggests movement toward recurring clinical usage. FDA 510(k) clearance and Brazilian regulatory clearance represent additional inflection points for market access, while the 2025 clinical coverage indicates continued attention to measurement accuracy and early intervention. The main uncertainty is the period after the Series A: public information does not establish subsequent fundraising, employee growth, revenue expansion, or major product launches. The current employee range of 11–50 and 10 current positions indicate a focused organization rather than a rapidly scaled commercial platform.